{"filing":{"accession_number":"0001193125-26-241867","cik":"0001671584","ticker":"APVO","company_name":"Aptevo Therapeutics Inc.","form":"8-K","filing_date":"2026-05-27","report_date":null,"primary_document":"apvo-20260525.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1671584/000119312526241867/apvo-20260525.htm"},"events":[{"id":8734,"run_id":7669,"accession_number":"0001193125-26-241867","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Aptevo entered into a material collaboration agreement with Niowave on May 25, 2026, involving joint development of a therapeutic product combining Aptevo's proprietary molecules (APVO455) and Niowave's radioisotopes (Actinium-225), coupled with a concurrent stock purchase agreement under which Niowave acquired 98,522 shares and 53,201 warrants for $500,000, with options for up to ~97,373 additional shares.","company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","filing_date":"2026-05-27","form":"8-K","submitted_at":null,"items":[{"id":1909,"accession_number":"0001193125-26-241867","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Aptevo entered into a material collaboration agreement with Niowave on May 25, 2026, involving development of a therapeutic product combining Aptevo's proprietary molecules (APVO455) and Niowave's radioisotopes (Actinium-225), coupled with a concurrent stock purchase agreement under which Niowave acquired 98,522 shares and 53,201 warrants for $500,000, with options for up to ~97,373 additional shares. While this is not a traditional M\u0026A transaction, the combination of a strategic collaboration, equity investment, and supply agreement constitutes a material transaction that would affect investor assessment of the company's strategic direction and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:14:31.412063+00:00","company_name":"","ticker":null,"filing_date":""},{"id":1910,"accession_number":"0001193125-26-241867","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses an unregistered sale of common stock to Niowave pursuant to a Stock Purchase Agreement, relying on the Section 4(a)(2) exemption for non-public offerings. This is a classic dilutive issuance under Item 3.02, and for a small-cap biotech company like Aptevo Therapeutics, such equity sales are material to investors assessing capital structure and ownership dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:14:31.412063+00:00","company_name":"","ticker":null,"filing_date":""},{"id":1911,"accession_number":"0001193125-26-241867","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The filing discloses transactions contemplated by a Collaboration Agreement, Supply Agreement, and Stock Purchase Agreement, with a press release issued on May 27, 2026. The forward-looking statements reference \"proceeds expected from the Stock Purchase Agreement\" and \"completion of the Niowave Private Placement and the transactions contemplated by the Stock Purchase Agreement,\" indicating material M\u0026A or capital-raising activity. While the Item 7.01 disclosure itself is limited, the reference to multiple transaction agreements and equity issuance suggests a material transaction requiring investor disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:14:31.412063+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1909,"accession_number":"0001193125-26-241867","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Aptevo entered into a material collaboration agreement with Niowave on May 25, 2026, involving development of a therapeutic product combining Aptevo's proprietary molecules (APVO455) and Niowave's radioisotopes (Actinium-225), coupled with a concurrent stock purchase agreement under which Niowave acquired 98,522 shares and 53,201 warrants for $500,000, with options for up to ~97,373 additional shares. While this is not a traditional M\u0026A transaction, the combination of a strategic collaboration, equity investment, and supply agreement constitutes a material transaction that would affect investor assessment of the company's strategic direction and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:14:31.412063+00:00","company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","filing_date":"2026-05-27"},{"id":1910,"accession_number":"0001193125-26-241867","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses an unregistered sale of common stock to Niowave pursuant to a Stock Purchase Agreement, relying on the Section 4(a)(2) exemption for non-public offerings. This is a classic dilutive issuance under Item 3.02, and for a small-cap biotech company like Aptevo Therapeutics, such equity sales are material to investors assessing capital structure and ownership dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:14:31.412063+00:00","company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","filing_date":"2026-05-27"},{"id":1911,"accession_number":"0001193125-26-241867","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The filing discloses transactions contemplated by a Collaboration Agreement, Supply Agreement, and Stock Purchase Agreement, with a press release issued on May 27, 2026. The forward-looking statements reference \"proceeds expected from the Stock Purchase Agreement\" and \"completion of the Niowave Private Placement and the transactions contemplated by the Stock Purchase Agreement,\" indicating material M\u0026A or capital-raising activity. While the Item 7.01 disclosure itself is limited, the reference to multiple transaction agreements and equity issuance suggests a material transaction requiring investor disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:14:31.412063+00:00","company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","filing_date":"2026-05-27"}]}